2-(4-(dimethylamino)benzylidene)malononitrile, also known as **DCM**, is a **bright yellow, crystalline solid** that's a key component in various research fields.
Here's why it's important:
**1. Dye and Pigment Applications:**
* **Coloring Agent:** DCM is a highly effective **colorant** used in various applications, including:
* **Dyes:** It provides brilliant yellow hues in textile dyeing, printing, and other coloring processes.
* **Pigments:** Its strong color and stability make it suitable for pigments used in paints, plastics, and inks.
**2. Optical Materials Research:**
* **Nonlinear Optics:** DCM exhibits strong **nonlinear optical properties**, meaning it can change the properties of light passing through it, making it useful in:
* **Optical switching:** Controlling light signals and data transmission.
* **Laser technology:** Enhancing the performance of lasers.
* **Optical data storage:** Developing new methods for storing and retrieving information using light.
**3. Organic Chemistry Research:**
* **Synthesis and Reactivity:** DCM is a versatile molecule used in organic synthesis as a starting material for various compounds.
* **Photochemistry:** Its sensitivity to light makes it useful for studying photochemical reactions and developing new photosensitive materials.
**4. Biological and Medicinal Chemistry:**
* **Biological Probes:** DCM's fluorescent properties make it a potential tool for studying biological processes and visualizing cell structures.
* **Drug Development:** Its structural features might be modified to develop new drugs with specific therapeutic effects.
**Importance in Specific Research Areas:**
* **Organic Electronics:** DCM's unique electronic properties are being investigated for applications in organic light-emitting diodes (OLEDs) and other organic electronic devices.
* **Solar Energy:** Researchers are exploring its potential in solar cell technologies to enhance efficiency and stability.
**In summary, 2-(4-(dimethylamino)benzylidene)malononitrile is a versatile compound with a broad range of applications across diverse research fields. Its vibrant color, strong nonlinear optical properties, and unique electronic properties make it a valuable tool for exploring new technologies and solutions in various scientific disciplines.**
2-(4-(dimethylamino)benzylidene)malononitrile: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 137736 |
| CHEMBL ID | 1461512 |
| SCHEMBL ID | 1227106 |
| MeSH ID | M0576479 |
| Synonym |
|---|
| AKOS000442790 |
| nsc 52860 |
| benzene, 1-dimethylamino-4-(2,2-dicyanoethenyl)- |
| UPCMLD0ENAT0500-7677:001 |
| HMS2568N11 |
| MS-7365 |
| benzene, 1-dimethylamino-4-(2,2-dicyanoethenyl) |
| p-n,n-dimethylaminobenzal malononitrile |
| nsc52860 |
| 2826-28-0 |
| nsc-52860 |
| DIVK1C_001853 |
| smr000185220 |
| [4-(dimethylamino)benzylidene]malononitrile |
| MLS000576193 |
| CDS1_000813 |
| MAYBRIDGE1_005565 |
| [4-(dimethylamino)benzylidene]propanedinitrile |
| STK326756 |
| HMS557E21 |
| FT-0690555 |
| 2-(4-(dimethylamino)benzylidene)malononitrile |
| NCGC00245590-01 |
| CHEMBL1461512 |
| 2-{[4-(dimethylamino)phenyl]methylidene}propanedinitrile |
| SCHEMBL1227106 |
| 4-dimethylaminobenzylidenemalononitrile |
| (4-dimethylaminobenzylidene)malodinitrile |
| 2-[4-(dimethylamino)benzylidene]malononitrile # |
| IYNONQVNLZATDK-UHFFFAOYSA-N |
| (4-dimethylaminobenzyliden)-malodinitril |
| 4-dicyanovinyl-n,n-dimethylaniline |
| DTXSID70182509 |
| mfcd00100708 |
| ((4-(dimethylamino)phenyl)methylene)methane-1,1-dicarbonitrile |
| 2-[4-(dimethylamino)benzylidene]malononitrile |
| 4-(n,n-dimethylamino)benzalmalononitrile |
| 2-[[4-(dimethylamino)phenyl]methylidene]propanedinitrile |
| 2-[4-(dimethylamino)phenyl]ethylene-1,1-dinitrile |
| F1638-0084 |
| CAA82628 |
| CS-0316268 |
| 1-cyano-2-[4-(dimethylamino)phenyl]vinyl cyanide |
| Z44300006 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 7.0795 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID634972 | Inhibition of West Nile virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-GLKRGG-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. |
| AID634971 | Inhibition of Dengue virus NS2B-NS3 protease expressed in Escherichia coli BL21 lambda (DE3) using Abz-NleKRRS-3-(NO2)Y as substrate at 50 uM preincubated for 15 mins before substrate addition measured up to 15 mins by spectrofluorimetry | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. |
| AID634973 | Inhibition of human thrombin using Boc-VPR-AMC as substrate at 25 uM preincubated for 15 mins before substrate addition measured up to 10 mins by spectrofluorimetry | 2011 | Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24 | Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||